Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.52 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | LAP3 | P28838 | 1/20 | 0.49 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.49 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.49 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2135194 | 1.00 | ALDH1A1 (0.58) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| Benzene SCHEMBL28241584 | 1.00 | ALDH1A1 (0.58) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| Hydrochloric Acid SCHEMBL629929 | 1.00 | ALDH1A1 (0.58) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| Hydrochloric Acid SCHEMBL16991480 | 1.00 | ALDH1A1 (0.58) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL728752 | 0.98 | ALDH1A1 (0.60) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL313062 | 0.98 | ALDH1A1 (0.60) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| SCHEMBL2135198 | 0.98 | ALDH1A1 (0.60) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| Cyclohexane SCHEMBL27529940 | 0.95 | ALDH1A1 (0.53) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| Alcohol SCHEMBL28297583 | 0.95 | ALDH1A1 (0.53) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 | |
| Hydrochloric Acid SCHEMBL21612229 | 0.95 | ALDH1A1 (0.56) | ALDH1A1KMT2AMAPK1L3MBTL1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109847455-B | Composite material for filtering fine particles, preparation method and application thereof | 四川大学 | 2021-07-06 | — | — | CN | claimed |
| CN-110201182-A | A kind of taxol-DHA- dextran coupling polymer and its synthetic method and application | 山东大学 | 2019-09-06 | — | — | CN | claimed |
| EP-3275864-B1 | COMPOUND OF 3-HYDROXYL PYRIDINE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO LTD (CN) | 2019-08-14 | — | — | EP | claimed |
| CN-109847455-A | A kind of composite material, preparation method and application for filtering fine particulates | 四川大学 | 2019-06-07 | — | — | CN | claimed |
| US-10149841-B2 | Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof | SHENYANG SUNSHINE PHARMACEUTICAL CO. LTD. (CN) | 2018-12-11 | — | — | US | claimed |
| US-20180117021-A1 | COMPOUND OF 3-HYDROXYL PYRIDINE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | SHENYANG SUNSHINE PHARMACEUTICAL CO., LTD. (CN) | 2018-05-03 | — | — | US | claimed |
| EP-3275864-A1 | COMPOUND OF 3-HYDROXYL PYRIDINE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | Shenyang Sunshine Pharmaceutical Co., Ltd. (CN) | 2018-01-31 | — | — | EP | claimed |
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4107164-B1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION (US) | 2025-04-24 | — | — | US | disclosed |
| US-12264173-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| WO-1992000278-A1 | NOVEL IMMUNOSUPPRESSIVE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1992-01-09 | — | — | WO | disclosed |
| EP-0094815-B1 | OLIGOPEPTIDE PRODRUGS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-01-11 | — | — | EP | disclosed |
| US-4766109-A | HYPOTENSIVE AGENTS | SCHERING CORPORATION (US) | 1988-08-23 | — | — | US | disclosed |
| CN-87102304-A | Pharmaceutical preparation containing compounds with antidementia effect and its application in preventing and treating cognitive dysfunction | — | 1987-12-30 | — | — | CN | disclosed |
| US-4479898-A | Oligopeptide prodrugs | SMITHKLINE BECKMAN CORPORATION (US) | 1984-10-30 | — | — | US | disclosed |
| US-4454065-A | INCREASE CELL MEMBRANE PERMEABILITY | SMITHKLINE BECKMAN CORPORATION (US) | 1984-06-12 | — | — | US | disclosed |
| EP-0094815-A2 | Oligopeptide prodrugs | SMITHKLINE BECKMAN CORPORATION (US) | 1983-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109724-A1 | ANTIVIRAL COMPOUNDS | IRF3, IFNAR1, HAVCR2 | SLC6A2 1633/4885SLC6A3 1192/4885CA2 3731/4885 |
| US-12264173-B2 | Antiviral compounds | MAVS, HAVCR2, ZC3HAV1 | SLC6A2 1045/4885SLC6A3 1463/4885CA2 4718/4885 |
| US-20250368604-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | SLC6A2 3250/4885SLC6A3 3828/4885CA2 2623/4885 |
| US-20250376443-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | SLC6A2 3321/4885SLC6A3 3983/4885CA2 2522/4885 |
| US-20180117021-A1 | COMPOUND OF 3-HYDROXYL PYRIDINE, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE THEREOF | EGLN3, EGLN2, P4HA1 | SLC6A2 3373/4885SLC6A3 2358/4885CA2 1510/4885 |
| US-10149841-B2 | Compound of 3-hydroxyl pyridine, preparation method thereof and pharmaceutical use thereof | EGLN3, EGLN2, P4HA1 | SLC6A2 3373/4885SLC6A3 2358/4885CA2 1510/4885 |
| US-20250129020-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | SLC6A2 3250/4885SLC6A3 3828/4885CA2 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.